Christopher M. Pieczonka

Urology

1226 E Water St
Syracuse, NY 13210

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 50 publications

Darolutamide With Concomitant Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer.

Darolutamide With Concomitant Lipid-Modifying Agents in Nonmetastatic Castration-Resistant Prostate Cancer.

Journal: JAMA network open

Published: August 19, 2026

Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide: Secondary End Points from the EMBARK Trial: Erratum.

Treatment of High-Risk Biochemically Recurrent Prostate Cancer with Enzalutamide in Combination with Leuprolide: Secondary End Points from the EMBARK Trial: Erratum.

Journal: The Journal of urology

Published: July 09, 2026

Germline genetic risk and prostate cancer-specific mortality in a population-based incident cohort.

Germline genetic risk and prostate cancer-specific mortality in a population-based incident cohort.

Journal: Prostate cancer and prostatic diseases

Published: March 05, 2026

Future opportunities and nuances with the use of PSMA PET in prostate cancer (MD PET 1).

Future opportunities and nuances with the use of PSMA PET in prostate cancer (MD PET 1).

Journal: Theranostics

Published: February 10, 2026

Reply by Authors.

Reply by Authors.

Journal: The Journal of urology

Published: February 06, 2026

Reply by Authors.

Reply by Authors.

Journal: The Journal of urology

Published: February 06, 2026

Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.

Aglatimagene besadenovec (CAN-2409) with radiotherapy for patients with localised prostate cancer: a phase 3, multicentre, randomised, double-blind, placebo-controlled trial.

Journal: The Lancet. Oncology

Published: January 06, 2026

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial.

Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial.

Journal: The Journal of urology

Published: December 09, 2025

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer.

Journal: The New England journal of medicine

Published: October 22, 2025

Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels.

Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels.

Journal: Current opinion in urology

Published: October 09, 2025

Erratum: TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.

Erratum: TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 09, 2025

TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.

TAR-200 for Bacillus Calmette-Guérin-Unresponsive High-Risk Non-Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: July 30, 2025

Showing 1-12 of 50

Last Updated: 09/26/2026